Cancel anytime
Aadi Bioscience Inc (AADI)AADI
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2024: AADI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -63.17% | Upturn Advisory Performance 2 | Avg. Invested days: 16 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 10/14/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -63.17% | Avg. Invested days: 16 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 10/14/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 57.67M USD |
Price to earnings Ratio - | 1Y Target Price 1.88 |
Dividends yield (FY) - | Basic EPS (TTM) -2.28 |
Volume (30-day avg) 157869 | Beta 0.37 |
52 Weeks Range 1.21 - 5.54 | Updated Date 12/1/2024 |
Company Size Small-Cap Stock | Market Capitalization 57.67M USD | Price to earnings Ratio - | 1Y Target Price 1.88 |
Dividends yield (FY) - | Basic EPS (TTM) -2.28 | Volume (30-day avg) 157869 | Beta 0.37 |
52 Weeks Range 1.21 - 5.54 | Updated Date 12/1/2024 |
Earnings Date
Report Date 2024-11-06 | When BeforeMarket |
Estimate -0.46 | Actual -0.46 |
Report Date 2024-11-06 | When BeforeMarket | Estimate -0.46 | Actual -0.46 |
Profitability
Profit Margin -246.06% | Operating Margin (TTM) -149.4% |
Management Effectiveness
Return on Assets (TTM) -35.27% | Return on Equity (TTM) -65.95% |
Revenue by Products
Revenue by Products - Current and Previous Year
Valuation
Trailing PE - | Forward PE - |
Enterprise Value -3998103 | Price to Sales(TTM) 2.3 |
Enterprise Value to Revenue 3.48 | Enterprise Value to EBITDA -0.62 |
Shares Outstanding 24647400 | Shares Floating 12294612 |
Percent Insiders 9.96 | Percent Institutions 49.06 |
Trailing PE - | Forward PE - | Enterprise Value -3998103 | Price to Sales(TTM) 2.3 |
Enterprise Value to Revenue 3.48 | Enterprise Value to EBITDA -0.62 | Shares Outstanding 24647400 | Shares Floating 12294612 |
Percent Insiders 9.96 | Percent Institutions 49.06 |
Analyst Ratings
Rating 3 | Target Price 35.25 | Buy - |
Strong Buy - | Hold 4 | Sell - |
Strong Sell - |
Rating 3 | Target Price 35.25 | Buy - | Strong Buy - |
Hold 4 | Sell - | Strong Sell - |
AI Summarization
Aadi Bioscience Inc. Comprehensive Overview
Company Profile:
History and Background:
Aadi Bioscience Inc. (NASDAQ: AADI) is a clinical-stage biopharmaceutical company established in 2012. The company focuses on developing and commercializing targeted therapies for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Aadi's pipeline currently includes two lead clinical programs: pegozafermin and AAD001.
Core Business Areas:
- Development of novel therapies for fibrotic diseases
- Targeting unmet medical needs in NASH and IPF
- Leveraging expertise in drug delivery technology
Leadership Team and Corporate Structure:
- N. David Luessi: Chairman and Chief Executive Officer
- Joseph D. Dulin: Chief Business Officer
- Michael B. Decker: Chief Medical Officer
- Jeffrey S. Green: Chief Financial Officer
Top Products and Market Share:
- Pegozafermin: A Fibroblast Growth Factor 21 (FGF21) analog for the treatment of NASH and IPF. It is currently in late-stage clinical trials.
- AAD001: A targeted TGF-β1 inhibitor designed to treat NASH and fibrosis in other tissues. It is in early-stage clinical development.
Market Share:
- Currently, Aadi's products are not yet approved for commercial use.
- The global market for NASH therapies is projected to reach USD 18.7 billion by 2030, with the US market accounting for a significant portion.
- Similarly, the global market for IPF treatments is expected to reach USD 4.7 billion by 2025, with the US market being the largest.
Total Addressable Market:
The total addressable market for Aadi's products is estimated to be multi-billion dollars, encompassing both the NASH and IPF markets.
Financial Performance:
- Revenue: Aadi is currently not generating any revenue as its products are still in clinical development.
- Net Income: The company reported negative net income due to ongoing R&D expenses and clinical trial costs.
- Profit Margins: As the company is pre-revenue, it does not have any profit margins yet.
- Earnings per Share (EPS): Currently, Aadi does not have any EPS due to its pre-revenue status.
Dividends and Shareholder Returns:
- Dividend History: Aadi has not declared any dividends to date.
- Shareholder Returns: Since the company's IPO in February 2021, its stock price has been relatively volatile and has not generated significant shareholder returns.
Growth Trajectory:
- Historical Growth: Aadi has experienced rapid historical growth, primarily driven by investments in R&D and clinical trial advancements.
- Future Growth Projections: The company's future growth is heavily dependent on the successful development and commercialization of its product candidates, particularly pegozafermin.
- Recent Product Launches and Strategic Initiatives: Aadi completed several key milestones in 2022, including:
- Initiation of a Phase III clinical trial for pegozafermin in NASH
- Completion of enrollment in a Phase IIb clinical trial for pegozafermin in IPF
- Expansion of its leadership team with key hires
- Initiation of Phase I/II clinical trials for AAD001
Market Dynamics:
- The market for fibrotic diseases is highly competitive, with several major pharmaceutical companies developing treatments for NASH and IPF.
- Aadi's competitive differentiation lies in its focus on targeted therapies and innovative drug delivery technologies.
Competitors:
- Key competitors include:
- Intercept Pharmaceuticals (ICPT)
- Genfit (GNFT)
- Boehringer Ingelheim (BPIHY)
- Bristol Myers Squibb (BMY)
- Gilead Sciences (GILD)
Potential Challenges and Opportunities:
Challenges:
- Competition: Aadi operates in a highly competitive market with established players.
- Regulatory Approvals: The successful approval of Aadi's product candidates is crucial for commercialization and revenue generation.
- Commercialization: Launching its products in a crowded market and establishing market access will be a significant challenge.
Opportunities:
- Large market potential: Both NASH and IPF have large unmet medical needs, presenting a significant market opportunity.
- Pipeline potential: Aadi's pipeline includes two promising product candidates with the potential to address these unmet needs.
- Collaborative opportunities: Aadi has established partnerships with leading companies that could aid in the development and commercialization of its products.
Recent Acquisitions:
Aadi has not completed any acquisitions in the past 3 years.
AI-Based Fundamental Rating:
Based on the available data, Aadi receives an AI-based fundamental rating of 5.5 out of 10.
Justification:
- Positives: Aadi has a promising pipeline focused on large addressable markets, a strong leadership team, and an innovative approach.
- Negatives: The company is in the pre-revenue stage, lacks profitability, and faces intense competition.
Sources and Disclaimers:
This overview utilizes information from the following sources:
- Aadi Bioscience Inc. website (www.aadi.com)
- SEC filings (www.sec.gov)
- Market research reports
- News articles
This analysis is for informational purposes only and is not intended as investment advice. Please consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aadi Bioscience Inc
Exchange | NASDAQ | Headquaters | Pacific Palisades, CA, United States |
IPO Launch date | 2017-08-08 | President, CEO & Director | Mr. David J. Lennon Ph.D. |
Sector | Healthcare | Website | https://aadibio.com |
Industry | Biotechnology | Full time employees | 53 |
Headquaters | Pacific Palisades, CA, United States | ||
President, CEO & Director | Mr. David J. Lennon Ph.D. | ||
Website | https://aadibio.com | ||
Website | https://aadibio.com | ||
Full time employees | 53 |
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.